Home › Funds › MPM BioImpact LLC › LQDA
MPM BioImpact LLC position in LQDA
LIQUIDIA CORPORATION · Health Care
MPM BioImpact LLC reported holding 1,386,174 shares of LQDA (LIQUIDIA CORPORATION) in its Q2 2026 13F filing — a position valued at US$110.5M, representing 6.74% of its reported portfolio and ranking #3 among its reported holdings. MPM BioImpact LLC has disclosed LQDA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's LQDA position evolved
MPM BioImpact LLC first disclosed a stake in LQDA in Q3 2025 at 200,000 shares (US$4.5M). The position peaked in Q2 2026 at 1,386,174 shares, worth US$110.5M. Across 4 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,386,174 shares valued at US$110.5M — a reduction of -18,984 shares quarter over quarter.. Notable position changes include a 600% increase in Q4 2025 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 200.00K | $4.55M | New |
| Q4 2025 | 1.40M | $48.32M | Add |
| Q1 2026 | 1.41M | $53.03M | Hold |
| Q2 2026 | 1.39M | $110.52M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LQDA and 13F data
LQDA (LIQUIDIA CORPORATION) is a Health Care company. 73 other funds we track also report a position in LQDA — the largest reported positions include Farallon Capital Management (US$666.9M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$666.9M), Caligan Partners LP (US$647.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LQDA
- Farallon Capital Management 8.37M sh · $666.94M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.37M sh · $666.94M · Q2 2026
- Caligan Partners LP 8.12M sh · $647.32M · Q2 2026
- Opaleye Management Inc. 2.45M sh · $195.14M · Q2 2026
- Caprock Group, LLC 1.41M sh · $112.40M · Q2 2026
- FINDELL CAPITAL MANAGEMENT LLC 1.30M sh · $103.66M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 622.72K sh · $49.65M · Q2 2026
- Eversept Partners, LP 428.65K sh · $34.18M · Q2 2026
- Seven Fleet Capital Management LP 256.60K sh · $20.46M · Q2 2026
- Capricorn Fund Managers Ltd 182.21K sh · $14.53M · Q2 2026
- APIS CAPITAL ADVISORS, LLC 140.00K sh · $11.16M · Q2 2026
- Diametric Capital, LP 105.78K sh · $8.43M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held LQDA?
MPM BioImpact LLC has disclosed LQDA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is MPM BioImpact LLC's current position in LQDA?
As of Q2 2026, MPM BioImpact LLC holds 1.39M shares of LQDA (LIQUIDIA CORPORATION), valued at $110.52M, representing 6.74% of its reported portfolio and ranking #3.
Has MPM BioImpact LLC been buying or selling LQDA?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in LQDA. The position peaked in Q2 2026 at 1.39M shares.
Which other funds hold LQDA?
Other major institutional holders of LQDA include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Caligan Partners LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.